LGND Quote, Financials, Valuation and Earnings

CNS Pharmaceuticals has a net margin of -13.84% compared to Ligand Pharmaceuticals's net margin of --. Ligand Pharmaceuticals's return on equity of 5.97% beat CNS Pharmaceuticals's return on equity of --.

Ligand Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 26.54%. On the other hand CNS Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 358.72%. Given that CNS Pharmaceuticals has higher upside potential than Ligand Pharmaceuticals, analysts believe CNS Pharmaceuticals is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 1.038, which suggesting that the stock is 3.81% more volatile than S&P 500. In comparison CNS Pharmaceuticals has a beta of 1.067, suggesting its more volatile than the S&P 500 by 6.725%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CNS Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. CNS Pharmaceuticals pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $51.8M, which are larger than CNS Pharmaceuticals quarterly revenues of --. Ligand Pharmaceuticals's net income of -$7.2M is lower than CNS Pharmaceuticals's net income of -$5.6M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 45.34x while CNS Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 13.48x versus -- for CNS Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pieris Pharmaceuticals has a net margin of -13.84% compared to Ligand Pharmaceuticals's net margin of -9230.19%. Ligand Pharmaceuticals's return on equity of 5.97% beat Pieris Pharmaceuticals's return on equity of -60.11%.

Ligand Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 26.54%. On the other hand Pieris Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 3229.37%. Given that Pieris Pharmaceuticals has higher upside potential than Ligand Pharmaceuticals, analysts believe Pieris Pharmaceuticals is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 1.038, which suggesting that the stock is 3.81% more volatile than S&P 500. In comparison Pieris Pharmaceuticals has a beta of 0.608, suggesting its less volatile than the S&P 500 by 39.216%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pieris Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Pieris Pharmaceuticals pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $51.8M, which are larger than Pieris Pharmaceuticals quarterly revenues of $53K. Ligand Pharmaceuticals's net income of -$7.2M is lower than Pieris Pharmaceuticals's net income of -$2.9M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 45.34x while Pieris Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 13.48x versus 0.51x for Pieris Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -13.84% compared to Ligand Pharmaceuticals's net margin of -63.65%. Ligand Pharmaceuticals's return on equity of 5.97% beat Revance Therapeutics's return on equity of --.

Ligand Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 26.54%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 148.77%. Given that Revance Therapeutics has higher upside potential than Ligand Pharmaceuticals, analysts believe Revance Therapeutics is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 1.038, which suggesting that the stock is 3.81% more volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $51.8M, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Ligand Pharmaceuticals's net income of -$7.2M is higher than Revance Therapeutics's net income of -$38.1M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 45.34x while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 13.48x versus 1.16x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks has a net margin of -13.84% compared to Ligand Pharmaceuticals's net margin of -186.56%. Ligand Pharmaceuticals's return on equity of 5.97% beat Zymeworks's return on equity of -27.06%.

Ligand Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 26.54%. On the other hand Zymeworks has an analysts' consensus of $19.86 which suggests that it could grow by 39.05%. Given that Zymeworks has higher upside potential than Ligand Pharmaceuticals, analysts believe Zymeworks is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 1.038, which suggesting that the stock is 3.81% more volatile than S&P 500. In comparison Zymeworks has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.109%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Zymeworks pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $51.8M, which are larger than Zymeworks quarterly revenues of $16M. Ligand Pharmaceuticals's net income of -$7.2M is higher than Zymeworks's net income of -$29.9M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 45.34x while Zymeworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 13.48x versus 17.20x for Zymeworks. Usually stocks with elevated PS ratios are considered overvalued.